tiprankstipranks
Trending News
More News >
Synlogic (SYBX)
NASDAQ:SYBX

Synlogic (SYBX) AI Stock Analysis

Compare
566 Followers

Top Page

SY

Synlogic

(NASDAQ:SYBX)

46Neutral
Synlogic faces significant challenges with persistent losses and negative cash flows, despite strong revenue growth and a debt-free balance sheet. Technical indicators suggest bearish sentiment, and valuation metrics are unfavorable due to ongoing unprofitability. The stock's potential is overshadowed by operational inefficiencies and financial difficulties.

Synlogic (SYBX) vs. S&P 500 (SPY)

Synlogic Business Overview & Revenue Model

Company DescriptionSynlogic (SYBX) is a clinical-stage biotechnology company focused on the development of Synthetic Biotic medicines, which are designed to treat diseases by programming probiotics to perform or deliver therapeutic functions in the gut. These engineered probiotics aim to address metabolic and immunological diseases, offering potential treatment options for conditions that are inadequately managed by traditional pharmaceuticals.
How the Company Makes MoneySynlogic makes money primarily through the development and potential commercialization of its Synthetic Biotic medicines. The company is engaged in partnerships and collaborations with other biotechnology and pharmaceutical firms to advance its research and development efforts, which can provide milestone payments and research funding. Additionally, Synlogic aims to generate revenue through licensing agreements and eventual sales of its therapeutic products upon successful clinical trials and regulatory approvals.

Synlogic Financial Statement Overview

Summary
Synlogic presents a mixed financial picture. While revenue growth is promising, profitability remains a challenge with persistent losses. The company benefits from a strong equity base without debt, providing some financial cushion. However, negative cash flows emphasize the need for careful cash management and operational improvements to achieve long-term viability.
Income Statement
45
Neutral
The income statement reveals a low revenue base with high growth (137.4% from 2023 to 2024) but persistent negative margins. The net profit margin remains negative at -291.99%, indicating ongoing unprofitability. The company is facing significant operational losses reflected in negative EBIT and EBITDA margins, pointing to inefficiencies and high fixed costs.
Balance Sheet
60
Neutral
The balance sheet shows a strong equity position with no debt, providing financial stability. Synlogic maintains a 64.31% equity ratio, indicating reliance on equity financing. However, the decreasing total assets over years may pose a risk if trends continue. The company maintains a healthy cash balance, critical for operations and strategic initiatives.
Cash Flow
50
Neutral
The cash flow statement highlights significant negative free cash flow, although improved from the previous year (-38.89%). The operating cash flow to net income ratio is negative, reflecting cash consumption in operations. The firm benefits from financing activities and investments, partially offsetting operational cash deficits. Strategic cash management remains crucial.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
8.00K3.37M1.18M1.75M545.00K
Gross Profit
8.00K3.37M-4.49M1.75M545.00K
EBIT
-40.95M-55.16M-67.42M-60.77M-60.47M
EBITDA
-23.01M-53.20M-63.63M-58.12M-57.83M
Net Income Common Stockholders
-23.36M-57.28M-64.88M-58.12M-56.54M
Balance SheetCash, Cash Equivalents and Short-Term Investments
18.86M47.75M77.63M136.63M100.44M
Total Assets
19.83M75.55M110.86M174.74M143.84M
Total Debt
0.0017.27M20.30M20.59M22.81M
Net Debt
-18.86M-6.68M4.44M4.16M-9.70M
Total Liabilities
7.08M32.90M28.25M27.47M28.70M
Stockholders Equity
12.75M42.66M82.61M147.27M115.14M
Cash FlowFree Cash Flow
-31.67M-51.83M-57.62M-52.88M-39.95M
Operating Cash Flow
-31.66M-51.61M-56.89M-52.20M-39.55M
Investing Cash Flow
25.34M38.77M58.35M-53.25M32.48M
Financing Cash Flow
172.00K20.94M-2.04M89.38M13.39M

Synlogic Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.08
Price Trends
50DMA
1.32
Negative
100DMA
1.37
Negative
200DMA
1.44
Negative
Market Momentum
MACD
-0.02
Positive
RSI
36.78
Neutral
STOCH
25.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.32, and below the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 25.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYBX.

Synlogic Risk Analysis

Synlogic disclosed 75 risk factors in its most recent earnings report. Synlogic reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Synlogic Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
$6.36B1.14-49.00%2.63%17.14%1.39%
46
Neutral
$12.63M-109.67%-99.76%76.96%
42
Neutral
$147.52M-187.83%-67.20%64.66%
41
Neutral
$686.32M-54.00%59.55%3.09%
39
Underperform
$12.87M-634.71%8.83%22.06%
39
Underperform
$85.47M-98.10%-58.64%-40.05%
36
Underperform
$48.46M-295.35%184.12%31.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SYBX
Synlogic
1.08
-0.66
-37.93%
SGMO
Sangamo Biosciences
0.66
0.10
17.86%
BLUE
Bluebird Bio
4.95
-18.25
-78.66%
CRIS
Curis
1.23
-15.27
-92.55%
EDIT
Editas Medicine
1.03
-5.69
-84.67%
NTLA
Intellia Therapeutics
6.63
-18.67
-73.79%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.